Fig. 1
From: SKA3 is a prognostic biomarker and associated with immune infiltration in bladder cancer
Pan-cancer SKA3 expression analysis. A SKA3 expression level in tumor and normal tissues in TCGA pan-cancer data using TIMER. B The comparison of RNA-seq expression levels between bladder cancer tissue (n = 404) and normal control tissue (n = 28), *indicates a significant difference (p < 0.05). C SKA3 protein level in normal urinary bladder tissues (quantity: none; intensity: negative; staining: not detected; antibody HPA03972). D SKA3 protein level in bladder urothelial carcinoma (quantity: 75%-25%; intensity: weak; staining: low; antibody: HPA03972). E SKA3 expression based on molecular subtypes on BLCA. F SKA3 expression based on TP53 mutation status of BLCA. *P < 0.05, **P < 0.01, ***P < 0.001